The macrophage plays a diverse array of roles in atherogenesis and lipoprotein metabolism. The macrophage functions as a scavenger cell, an immune mediator cell, and as a source of chemotactic molecules and cytokines. Chemokines have been implicated in promoting migration of monocytes into the arterial intima. Monocyte chemoattractant protein-1 (MCP-1) attracts monocytes bearing the chemokine receptor CCR-2. Macrophage expression of cyclooxygenase-2, a key enzyme in inflammation, promotes atherosclerotic lesion formation in low-density lipoprotein receptor (LDLR)-deficient mice. In the arterial intima, monocytes differentiate into macrophages, which accumulate cholesterol esters to form lipid-laden foam cells. Foam cell formation can be viewed as an imbalance in cholesterol homeostasis. The uptake of atherogenic lipoproteins is mediated by scavenger receptors, including SR-A and CD36. In the macrophage, ACAT-1 is responsible for esterifying free cholesterol with fatty acids to form cholesterol esters. Surprisingly, deficiency of macrophage ACAT-1 promotes atherosclerosis in LDLR-deficient mice. A number of proteins have been implicated in the process of promoting the efflux of free cholesterol from the macrophage, including apoE, ABCA1, and SRB-1. Macrophage-derived foam cells express the adipocyte fatty acidbinding protein (FABP), aP2, a cytoplasmic FABP that plays an important role in regulating systemic insulin resistance in the setting of obesity. ApoE-deficient mice null for macrophage aP2 expression develop significantly less atherosclerosis than controls wild type for macrophage aP2 expression. These results demonstrate a significant role for macrophage aP2 in the formation of atherosclerotic lesions independent of its role in systemic glucose and lipid metabolism. Furthermore, macrophages deficient in aP2 display alterations in inflammatory cytokine production. Through its distinct actions in adipocytes and macrophages, aP2 links features of the metabolic syndrome including insulin resistance, obesity, inflammation, and atherosclerosis.
Introduction
Atherosclerosis is an inflammatory disease process. 1 The monocyte/macrophage plays key roles both in the initiation and progression of atherosclerosis. Recruitment of monocytes into the artery wall is one of the earliest events in atherosclerosis. In the intima, monocytes develop into macrophages, which are important mediators of inflammation and the innate (antigen-independent) immune response in atherosclerosis. Macrophages contribute to the local inflammatory responses through production of cytokines, free oxygen radicals, proteases, and complement factors. By serving as antigen-presenting cells, macrophages participate in the acquired immune response. The uptake of modified lipoproteins by macrophages leads to the accumulation of cholesterol esters and formation of macrophage-derived foam cells, the hallmark of the fatty streak. Macrophages also contribute to lesion remodeling and to plaque rupture by secreting matrix metalloproteinases. Thus, macrophages contribute to the evolution of atherosclerosis in diverse ways. Murine models of atherosclerosis have proven useful in identifying genes expressed by macrophages that contribute to these diverse functions and the pathogenesis of atherosclerosis, providing new potential therapeutic targets for the prevention and treatment of atherosclerosis. 2 
Monocyte recruitment
Insults to the endothelium, such as hypercholesterolemia, stimulate the production of leukocyte chemoattractant molecules, which activate receptors on rolling monocytes leading to integrin-dependent firm adhesion to the endothelium and subsequent diapedesis into the subendothelium. 1 Chemokines are a family of low molecular weight chemotactic cytokine proteins that are involved in the recruitment of leukocytes to sites of inflammation. 
Macrophages and cytokines
Once inside the arterial intima, monocytes differentiate into macrophages under the influence of the cytokine, macrophage colony-stimulating factor (MCS-F). 6 Op/op mice lack MCS-F and are deficient in tissue macrophages. Evidence for the crucial role of macrophage differentiation in atherosclerosis was provided by the demonstration that mice deficient for both apoE and MCS-F (op/op) are dramatically protected from atherosclerosis despite high levels of cholesterol. 7 Cells in arterial lesions express both CD40 and CD40L, members of the TNFa/TNFa-receptor family. 8 CD40
activation leads to increased T-cell production of interferon (IFN)g, which induces macrophage activation. 
Cyclooxygenase-2
Cyclooxygenase (COX) regulates the production of eicosanoids, which modulate physiologic processes in the vessel wall contributing to atherosclerosis and thrombosis. COX exists in two isoforms, COX-1 and COX-2, which are encoded by two separate genes. 13 COX-1 is constitutively expressed in most tissues mediating 'housekeeping' functions of the cells, whereas COX-2 expression is rapidly induced during inflammation by a variety of agents, including cytokines, mitogens, and prostoglandins (PGs). COX-1 mediates production of platelet thromboxane (Tx) A 2 , a potent vasoconstrictor and platelet agonist. Both COX-1 and COX-2 contribute to production of endothelial prostacyclin (PGI 2 ), a vasodilator that inhibits platelet activation. The beneficial effects of aspirin in reducing cardiovascular events are widely attributed to its ability to irreversibly inhibit platelet TxA 2 production. However, it has been suggested that some of the beneficial effects of aspirin on coronary events may stem from its anti-inflammatory effects. Nearly three decades ago, NSAIDs were reported to decrease atherosclerosis in cholesterol-fed rabbits, indicating that nonselective inhibition of COX reduces atherosclerosis in this animal model. Concerns have been raised that COX-2 inhibitors may increase thrombotic cardiovascular events by disturbing the balance between platelet TxA 2 and endothelial PGI 2 , but further clinical trials will be required to resolve this controversial issue. 13 COX-2 is upregulated in activated monocyte/macrophages. The proinflammatory agents IL-1, TNFa, and lipopolysaccharide (LPS), as well as the growth factors transforming growth factor (TGFb), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), have all been shown to induce COX-2 expression in monocytes, whereas COX-2 expression is inhibited by the anti-inflammatory cytokines IL-4 and IL-13 and by glucocorticoids. COX-2-mediated PG production by activated macrophages in the artery wall may promote atherosclerosis through a number of mechanisms including activation of chemotaxis, induction of vascular permeability, propagation of the inflammatory cytokine cascade, and stimulation of SMC migration, proliferation, and synthesis of extracellular matrix. Recently, we examined the distribution of COX-2 expression in atherosclerotic lesions of apoE À/ À mice. Similar to the studies in humans, COX-2 is expressed by endothelial cells, smooth muscle cells, and monocyte/ macrophages in mouse atherosclerotic lesions but not in normal arteries.
14 Interestingly, the majority of macrophagederived foam cells did not express COX-2, an observation consistent with the in vitro data that oxidized LDL suppresses COX-2 expression in human monocyte-macrophages. 15 We have recently examined the hypothesis that pharmacological inhibition of COX-2 in LDL-receptor negative (LDLR À/À ) mice would reduce early atherosclerosis. 14 After 6 weeks on a Western-type diet, male LDLR À/À mice treated with either rofecoxib (a selective COX-2 inhibitor) or indomethacin (a nonselective COX inhibitor) had significant 25-50% reductions in atherosclerosis when compared to control mice. In these inhibitor studies, we provided evidence that rofecoxib was indeed selective for COX-2, as there was no inhibition of platelet or urinary Tx production.
Thus, our studies demonstrate a role for COX-2-dependent prostanoid formation in promoting atherogenesis. Consistent with our studies, Pratico et al 16 reported a trend for a reduction in atherosclerosis in LDL-deficient mice treated with nimesulide, and Krul et al 17 have recently presented data that treatment of apoE-deficient mice with a selective COX-2 inhibitor, celecoxib, results in a significant reduction in aortic atherosclerosis. Also, we generated LDLR À/À mice null for macrophage COX-2 by fetal liver cell transplantation to examine the role of macrophage COX-2 expression in atherosclerosis. Similar to the inhibitor studies, COX-2 À/À -LDLR À/À mice had significantly less atherosclerosis than control COX-2 þ / þ -LDLR À/À mice after 8 weeks on the Western diet, providing genetic evidence in support of a proatherogenic role for macrophage COX-2 expression. As COX-2 is downregulated in macrophage-derived foam cells, it is likely that the proatherogenic effects of macrophage COX-2 expression are mediated through promotion of the local inflammatory response in steps prior to foam cell formation. These results support the potential of antiinflammatory approaches for the prevention of atherosclerosis and identify COX-2 as a target for intervention.
Macrophage foam cell formation and cholesterol homeostasis
Maintenance of cholesterol homeostasis is a challenge for all peripheral cells, and is particularly important in the macrophage. In addition to the usual excess of free cholesterol resulting from intracellular membrane turnover, the macrophage is exposed to large amounts of cholesterol derived from cell debris or lipoprotein material. The rapid internalization of this cholesterol cargo affects macrophage viability and function, and is an important element in the process of foam cell formation. Since the control of cholesterol efflux is of vital relevance in the macrophage, it is possible that macrophage-specific mechanisms of cholesterol efflux may be at play to regulate lipid homeostasis more efficiently in this cell type. The discovery of ABC-A1 has led to intense interest in its role in cholesterol efflux from the macrophage. 18 Recent studies by Francone and co-workers 19 have shown that inactivation of macrophage ABC-A1 promotes increased atherosclerosis in apoE-deficient mice. Although ABC-A1 appears to be an important mediator of cholesterol delivery to apoAI and the nascent HDL, the efflux system in the macrophage is probably redundant, and additional drivers of cholesterol elimination are involved. ApoE is highly expressed by macrophages, is an acceptor of intracellular cholesterol, is a component of HDL, and is involved in local regulation of inflammation. ApoE has a functional role in the artery wall apart from its more systemic effects on lipoprotein clearance. Bone marrow transplantation studies demonstrated that macrophage apoE is sufficient to normalize cholesterol and prevent atherosclerosis in apoE-deficient mice. 20 Furthermore, the removal of macrophage apoE increases lesion size in C57BL/6 mice on a high-fat diet, 21 as well as in apoAI
, apoAI overexpressing, and LDL-R À/À mice. 22, 23 Expression of very low levels of murine or human apoE from retrovirus-transduced macrophages in apoE-null mice results in decreased lesion area during the early stages of atherosclerosis. 24 This effect is not observed if the human apoE is defective in LDLR-(apoE2) or proteoglycan-binding ability (apoEcys142), thus suggesting that proximity to the plasma membrane is essential for the biologic action of apoE in the vessel wall. 25 Moreover, we have recently shown that a physiologically normal expression of macrophage apoE has antiatherogenic effects that are not limited to the foam cell lesion but extend into the more advanced stages of plaque growth. 26 Macrophage apoE expression is regulated by cellular cholesterol. 27 Two distal enhancers that specify apoE gene expression from macrophages contain conserved liver X receptor (LXR) response elements. 28 There may be a noncooperative assignment to macrophage cholesterol homeostasis for both apoE and ABC-A1, as the absence of apoE causes increased levels of ABC-A1 protein, whereas the expression of apoE reduces ABC-A1 levels. 29 ApoE may be the primary driver of cholesterol efflux in macrophages through a pathway independent from ABC-A1. However, our recent observations that the transgenic or retrovirus-based expression of apoAI from the macrophage corrects the increased atherosclerosis induced by deletion of apoE from the same cell type 22, 23 support the notion that apoE-induced cholesterol efflux is quantitatively in the same range as that obtainable through ABCA1-dependent (apoAI-mediated) events. It has been determined that both apoE and ABCA1 genes are regulated by the PPARg-LXR axis, and the macrophage-specific deletion of PPARg reduces levels of apoE and ABCA1 mRNAs, and drastically decreases basal cholesterol efflux. 30 In addition to its effects on cholesterol accumulation in macrophages, apoE can also modulate immune and inflammatory responses. 31 It is plausible that apoE might act as a 'translation' molecule capable of sensing and modulating both cholesterol homeostasis and inflammatory changes in the macrophage. Delivery of cholesterol out of the cell and into the reverse cholesterol pathway is seen as dependent on the forces that affect the balance between free and esterified cholesterol in the cell. After hydrolysis of lipoprotein cholesterol esters by the lysosomal acid lipase, free cholesterol released is reesterified by ACAT for storage in vesicular depots. Although deletion or inhibition of ACAT should increase cholesterol efflux via increased accumulation of intracellular free cholesterol, we have shown that elimination of ACAT1 from macrophages of LDLR À/À mice increased arterial lesions and reduced the number of arterial macrophages, likely because of accelerated apoptosis. 32 Feng and Tabas 33 have reached similar conclusions by showing that cholesterol loading in macrophages induces accumulation of free cholesterol and provokes 'toxic' effects including accelerated degradation of ABCA1 protein and reduced efflux of cholesterol from the cell.
Adipocyte fatty acid-binding protein, aP2
Cytoplasmic fatty acid-binding proteins (FABP) are a family of 14-15 kDa proteins that bind fatty acid ligands with high affinity. Putative functions of FABPs include (1) shuttling of fatty acids to specific enzymes and cellular compartments, (2) modulation of intracellular lipid metabolism, and (3) regulation of gene expression. 34 The adipocyte FABP aP2 has important effects on insulin resistance, lipid metabolism, and atherosclerosis. 34 Lack of aP2 reduces the hyperinsulinemia and insulin resistance associated with dietary or genetic obesity in mice, but these effects of aP2 on insulin sensitivity and lipid metabolism are not seen in lean mice. 35, 36 Another FABP, mal1 (keratinocyte FABP, psoriasisassociated FABP and epidermal FABP), is also present in adipocytes but at lower abundance than aP2. 35 mal1 is highly homologous to aP2, and they both bind a variety of fatty acids and synthetic compounds with similar affinities. Interestingly, mal1 protein and gene expression are dramatically increased in aP2 À/À adipocytes. 35, 37 This induction probably represents a compensatory response of the adipocytes that replaces some but not all functions of the aP2 protein.
Considerable evidence supports a striking overlap between the biology of adipocytes and macrophages. Several genes that are critical in adipocytes including transcription factors, cytokines, inflammatory molecules, nuclear receptors, fatty acid transporters, and scavenger receptors are also expressed in macrophages and play a significant role in their biology. Therefore, we investigated aP2 expression and regulation in primary isolated macrophages and macrophage cell lines. 38 In both THP-1 and U-937 human monocyte/macrophage cell lines and in primary human and mouse monocytes, aP2 and mal1 expressions were not detected in resting cells but became evident after stimulation with PMA. Unlike the compensatory regulation in adipocytes, mal1 mRNA did not appear to be significantly upregulated in aP2 À/À primary macrophages. 38 Next, we examined whether the aP2 deficiency has functional consequences in macrophage biology that might influence the development of atherosclerosis. Expression of several inflammatory cytokines, including TNFa, IL-1b, MCP-1, and IL-6 was significantly reduced in aP2 À/À macrophages, both in the resting state and in response to PMA stimulation, indicating a reduced inflammatory capacity of aP2 À/À macrophages. 38 The contribution of aP2 to macrophage cholesterol ester accumulation was assayed in acetylated low-density lipoprotein (Ac-LDL)-loaded macrophages from wild-type and aP2 À/À mice. In the absence of lipid loading, the cholesterol ester levels in the aP2 À/À cells were 29% lower than in aP2 þ / þ cells, and aP2 À/À macrophages responded to Ac-LDL loading with 37% less accumulation of cholesterol ester compared to the aP2
controls. 38 The levels of aP2 and mal1 protein expression
were not affected by Ac-LDL loading in the aP2 À/À or aP2
macrophages. Thus, elimination of aP2 decreased intracellular cholesterol ester accumulation in macrophages despite the presence of mal1 protein.
Next we examined whether macrophage aP2 is sufficient to modulate the development of atherosclerosis in a way that is independent from the metabolic consequences of aP2-deficiency. We have examined this issue in two different models. First, we studied the effect of aP2 deficiency on the development of atherosclerosis in apoE À/À mice on normal chow diet. Under these experimental conditions, male aP2 À/ À apoE À/À mice developed 66% less atherosclerosis in crosssections of the proximal aorta and 86% smaller lesions by en face analysis of the extent of lesions in the entire aorta compared to control aP2 þ / þ apoE À/À mice, despite severe hypercholesterolemia. 38 These dramatic changes in the extent of atherosclerosis occurred in the absence of significant changes in serum lipid, glucose, or insulin levels, indicating that aP2 expression can contribute to atherosclerosis independent of its established role in glucose and lipid metabolism.
To examine the hypothesis that macrophage aP2 expression promotes atherogenesis independent of its expression by adipocytes, we generated apoE-deficient mice null for macrophage-aP2 expression through bone marrow transplantation experiments. 38 Male apoE À/À mice reconstituted with aP2 À/À macrophages had a 43% and 49% reduction in lesion area compared to those reconstituted with aP2
þ / þ cells as assessed in the proximal aorta and in the entire aorta en face, respectively. In female aP2
mice, there was a trend for a reduction in the extent of atherosclerosis in the proximal aortas, but it was not statistically significant. However, there was a significant 48% reduction in mean lesion area in en face analysis of the aortas in female aP2
À/À apoE À/À -apoE À/À mice compared to female aP2 þ / þ apoE À/À -apoE À/À mice. 38 To determine if aP2 deficiency has a similar effect in the setting of advanced atherosclerosis and severe hypercholesterolemia, male and female mice deficient in both aP2 and apoE as well as apoEdeficient controls were fed a Western diet for 14 weeks. No significant differences in fasting cholesterol, triglycerides, free fatty acids, glycerol, or glucose were found between groups for each sex. Feeding the Western diet to these mice caused no significant reduction in insulin sensitivity in vivo by insulin tolerance testing. Both male and female aP2 À/ À apoE À/À mice had significant reductions in mean atherosclerotic lesion size in the proximal aorta, en face aorta, and innominate/right carotid artery compared to apoE À/À controls. 39 These data demonstrate an important role for aP2 expression in the advanced stages of atherosclerotic lesion formation. Thus, aP2 provides an important physiologic link between different features of the metabolic syndrome and is a potential therapeutic target for vascular protection.
Conclusion
Atherosclerotic arteries manifest cellular and biochemical features of inflammation. As the macrophage has both scavenging and immunologic functions, this cell type may represent the link between intracellular cholesterol accumulation and activation of the inflammatory pathway. In addition, the macrophage might be involved in the accelerated vascular problems of the insulin resistance syndrome, as shown by the reduction in atherosclerosis seen in hyperlipidemic mice carrying a deletion in macrophage aP2. This body of evidence points to the macrophage as a viable target for therapeutic intervention aimed at treating or preventing atherosclerosis.
